MARKET

AGLE

AGLE

Aeglea Bio
NASDAQ

Real-time Quotes | Nasdaq Last Sale

7.21
+0.06
+0.84%
Opening 12:20 03/05 EST
OPEN
7.25
PREV CLOSE
7.15
HIGH
7.25
LOW
7.07
VOLUME
101.54K
TURNOVER
--
52 WEEK HIGH
11.38
52 WEEK LOW
3.500
MARKET CAP
345.63M
P/E (TTM)
-3.7723
1D
5D
1M
3M
1Y
5Y
8-K: Aeglea BioTherapeutics, Inc.
(EDGAR Online via COMTEX) -- false 0001636282 0001636282 2021-02-23 2021-02-23 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 02/25 01:03
Aeglea BioTherapeutics Appoints Sara Brownstein to Board of Directors
AUSTIN, Texas, Feb. 24, 2021 /PRNewswire via COMTEX/ -- AUSTIN, Texas, Feb. 24, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a...
PR Newswire - PRF · 02/24 21:30
Steven Cohen Dives Into Chimerix
GuruFocus News · 02/24 15:02
We Think Aeglea BioTherapeutics (NASDAQ:AGLE) Needs To Drive Business Growth Carefully
Simply Wall St. · 02/18 06:45
10 Best Small-Cap Biotech Stocks Under $10 in 2021
In this article we will list the 10 best small-cap biotech stocks under $10 in 2021. Click to skip ahead and see the 5 Best Small-Cap Biotech Stocks Under $10 in 2021. We like healthcare and technology industries because of their above-average long-term gr...
Insider Monkey · 02/08 15:11
Aeglea Biotherapeutics CFO Charles York to step down
Aeglea BioTherapeutics (AGLE) announces that the company's chief financial officer, Charles York, will be stepping down from his role effective February 12, 2021.Aeglea has initiated a search process to identify
Seekingalpha · 02/03 21:38
Aeglea BioTherapeutics Initiated Search Process to Identify New Chief Fincl Officer >AGLE
Aeglea BioTherapeutics Initiated Search Process to Identify New Chief Fincl Officer >AGLE
Dow Jones · 02/03 21:32
Aeglea BioTherapeutics: Steven Weber Appointed to Serve as Principal Acctg Officer
Aeglea BioTherapeutics: Steven Weber Appointed to Serve as Principal Acctg Officer
Dow Jones · 02/03 21:32
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AGLE. Analyze the recent business situations of Aeglea Bio through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AGLE stock price target is 14.14 with a high estimate of 25.00 and a low estimate of 9.00.
EPS
Institutional Holdings
Institutions: 136
Institutional Holdings: 42.97M
% Owned: 89.65%
Shares Outstanding: 47.94M
TypeInstitutionsShares
Increased
31
2.69M
New
22
2.86M
Decreased
29
2.85M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.52%
Pharmaceuticals & Medical Research
+0.05%
Key Executives
Chairman/Independent Director
Russell Cox
President/Chief Executive Officer/Director
Anthony Quinn
Chief Operating Officer
Leslie Sloan
Vice President/Controller
Steven Weber
Other
Michael Hanley
Other
Ravi Rao
Director
Sara Brownstein
Director/IR Contact Officer
Joey Perrone
Director
Alison Lawton
Independent Director
Suzanne Bruhn
Director
Bryan Lawlis
Independent Director
V. Bryan Lawlis
Independent Director
Ivana Magovcevic-Liebisch
Independent Director
Sandesh Mahatme
Independent Director
Armen Shanafelt
No Data
About AGLE
Aeglea BioTherapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing a human enzyme therapeutics as advanced solutions for rare and other high-burden diseases. The Company’s product candidates are Pegzilarginase, ACN00177 and AEB5100. Its Pegzilarginase is a recombinant human Arginase one that enzymatically degrades the amino acid arginine to lower arginine levels in patients with Arginase One Deficiency. Its engineered pegzilarginase with modifications that enhance the stability and arginine-degrading activity of the enzyme in human plasma. The Company is evaluating Pegzilarginase in a global pivotal Phase III PEACE (Pegzilarginase Effect on Arginase one Deficiency Clinical Endpoints) trial and in a Phase II open-label extension study for patients with Arginase One Deficiency. Its ACN00177 is a PEGylated or polyethylene glycol modified, human enzyme engineered to degrade free homocysteine and homocystine in patients with Homocystinuria.

Webull offers kinds of Aeglea Bio Therapeutics Inc stock information, including NASDAQ:AGLE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AGLE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AGLE stock methods without spending real money on the virtual paper trading platform.